Drug intelligence / Profile preview

BL-0161

Development stage: Preclinical
Lead developer: Shanghai Bestlink Biotechnology

Overview

BL-0161 is a preclinical-stage drug candidate developed by Shanghai Best-Link Bioscience for the treatment of solid tumors. As of early 2024, the specific molecular target, mechanism of action, and modality of BL-0161 have not been publicly disclosed by the developer. The candidate is part of a pipeline that leverages technology platforms focused on small molecule drugs and drug conjugates to address advanced malignancies and other therapeutic areas such as endocrinology.

Targets

ER (Estrogen receptor)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on BL-0161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-0161.

Explore the full profile